Chen, A. 2025. CD19 And CD22 Dual-Target CAR-T Therapy Via CRISPR/Cas9 Engineering for Relapsed B-Cell Acute Lymphoblastic Leukemia. Academic Journal of Science and Technology. 18, 1 (Dec. 2025), 621–625. DOI:https://doi.org/10.54097/79zwp242.